Drugs / Ganzhixiao Capsule
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06848907 | May 2025 → May 2028 expected | metabolic dysfunction-associated steatotic liver disease | Dong Hui | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ganzhixiao Capsule | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06848907 ↗ |
| Route | Oral | “Take 3 capsules each in the morning, afternoon, and evening, and swallow with warm water after meals for 16 weeks.” NCT06848907 ↗ |